Share on StockTwits

Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Shalini Sharp sold 4,000 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $53.97, for a total transaction of $215,880.00. Following the completion of the sale, the chief financial officer now directly owns 80,255 shares of the company’s stock, valued at approximately $4,331,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Robert W. Baird initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 15th. They set an “outperform” rating and a $64.00 price target on the stock. Five analysts have rated the stock with a buy rating, Ultragenyx Pharmaceutical currently has an average rating of “Buy” and an average price target of $74.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 0.23% during mid-day trading on Tuesday, hitting $55.88. 608,816 shares of the company’s stock traded hands. Ultragenyx Pharmaceutical has a 1-year low of $32.02 and a 1-year high of $69.774. The stock has a 50-day moving average of $46.13 and a 200-day moving average of $45.48. The company’s market cap is $1.772 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Monday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.03. On average, analysts predict that Ultragenyx Pharmaceutical will post $-2.06 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.